SEC Form 4 · accession 0001209191-17-061637
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas F Kearns Jr.
Director
Period of report
Nov 15, 2017
Accepted (ET)
Nov 17, 2017 · 7:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 15, 2017 | M | 18,000 | $2.35 | A | 156,564 | D | |
| Common StockF1 | Nov 15, 2017 | S | 18,000 | $45.22 | D | 138,564 | D | |
| Common Stock | holding | — | — | — | 110,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $2.35 | Nov 15, 2017 | M | 12,000 | D | — | Mar 12, 2018 | Common Stock | 12,000 | 0 | D |
| Stock Option (Right to Buy)F2 | $2.35 | Nov 15, 2017 | M | 6,000 | D | — | Mar 12, 2018 | Common Stock | 6,000 | 0 | D |
Explanation of responses
- F1The shares were sold at prices ranging from $44.85 to $45.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2Fully vested.